Answers are grounded in this paper and cite their sources.
Background Multiple sclerosis (MS) involves peripheral immune activation, central nervous system (CNS) inflammation, and incomplete repair. This narrative review integrates evidence on betaine-linked one-carbon metabolism across adaptive immunity, lesion-associated myeloid cells, and the oligodendrocyte lineage to identify supported mechanisms, unresolved connections, and priorities for experimental validation. Main body Betaine contributes to systemic homocysteine remethylation through betaine-homocysteine methyltransferase (BHMT), which is expressed predominantly in the liver and kidney. In a high-dose experimental autoimmune encephalomyelitis (EAE) study, preventive betaine treatment reduced disease severity, dendritic cell interleukin-6 production, and T helper 17 (Th17) differentiation; treatment after disease onset did not improve established disease. Independent methionine restriction experiments demonstrated regulation of T-cell S-adenosylmethionine availability and inflammatory chromatin programming. Together, these studies identify immune signaling and methionine-dependent epigenetic regulation as complementary subjects for mechanistic investigation, with cellular activation state and methylation target guiding interpretation. Studies using cuprizone models reported metabolic, neuronal, inflammatory, and structural outcomes, while oligodendrocyte experiments identified maturation-related molecular responses. Betaine studies in predominantly non-MS microglial models provide a rationale for examining inflammatory signaling in demyelinating settings. A descriptive audit of selected public human brain transcript resources identified sparse BHMT transcript detection, informing priorities for protein localization and enzyme activity studies in MS lesion cells. Human dietary and metabolite studies provide association-level evidence, while human pharmacology characterizes systemic exposure and biochemical responses and informs safety monitoring. Conclusions This review integrates the available evidence into a testable framework that distinguishes systemic metabolism from cell-intrinsic mechanisms and considers cellular activation state. The examined EAE evidence identifies dendritic cell-derived interleukin-6 as an experimentally supported betaine-linked immune entry point, while hepatic mediation remains a separate hypothesis. Matched interventions, cell-resolved flux measurements, and selective perturbations would help distinguish immune modulation, tissue preservation, and remyelination. This framework provides a focused research agenda for determining whether and how betaine-linked metabolism influences demyelinating neuroinflammation and its relevance to MS.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: